Pharmagen, Inc. announced earnings results for the first quarter ended March 31, 2013. For the quarter, on consolidated basis, revenues totaled $1.72 million as compared to the three months ended March 31, 2012, representing a 329% increase year-over-year. Operating loss was $666,000.

Adjusted for nonrecurring expenses, and depreciation and amortization, the company reported a slight profit for the quarter on an EBITDA basis.